22.01.2022 | ASO Author Reflections
ASO Author Reflections: Minimally Invasive Secondary Cytoreductive Surgery for Ovarian Cancer Lymph Node Recurrence: Shaping Treatment with All Arrows in our Quiver
verfasst von:
Matteo Loverro, MD, Raffaella Ergasti, MD, Carmine Conte, MD, Vitalba Gallitelli, MD, Dania Nachira, MD, Giulia Scaglione, MD, Anna Fagotti, MD, Giovanni Scambia, MD, Valerio Gallotta, MD
Erschienen in:
Annals of Surgical Oncology
|
Ausgabe 4/2022
Einloggen, um Zugang zu erhalten
Excerpt
Despite the advances in cytoreductive efforts and the potential addition of bevacizumab and poly(ADP)-ribose polymerase (PARP) inhibitors to front-line platinum-based regimens, the vast majority of patients with advanced ovarian cancer (OC) relapse and succumb to the disease within 5 years from the initial diagnosis. …